AI drug discovery company Syntekabio has partnered with Ukraine-based global compound supplier Enamine for supply, synthesis of compounds and synthetic drug development.

Under the Memorandum of Understanding (MOU) signed by the companies, the alliance will leverage an extensive synthetic compound library provided by Enamine to support drug candidate discovery services through Syntekabio's AI platform, DeepMatcher.

Syntekabio and Enamine will work at the AI Bio Supercomputer Center (ABS Center) in Daejeon, South Korea.

Their aim is to derive optimised lead compounds for drug development, combining Syntekabio's AI capabilities with Enamine's chemical synthesis and preclinical biology services.

The companies also plan joint marketing to accelerate their expansion in the global market for AI-driven drug discovery services.

Enamine is growing its global presence with branches in the US, Germany and Poland.

Its comprehensive services include in vitro efficacy verification, binding assays and ADMET [absorption, distribution, metabolism, excretion and toxicity] screening.

Enamine will apply its knowledge in chemical, custom synthesis and preclinical biology services to work with Syntekabio on therapeutic optimisation and extraction of lead compounds utilising the AI-based molecular design technology of Syntekabio.

Syntekabio is also conducting bio-drug research using its NEO-ARS and Ab-ARS services.

NEO-ARS is a personal and shared neoantigen prediction service. Ab-ARS focuses on new antibody discovery and optimisation research.

Enamine business development director Dr Iaroslava Kos stated: “We are excited to collaborate with Syntekabio to integrate our extensive compound library with their advanced AI platform.

“This partnership aims to accelerate the discovery of optimised lead compounds, enhancing the efficiency and effectiveness of drug development. By combining our strengths, we look forward to making significant advancements in the field of synthetic drug development.”